Physician profile
Nicole T Eiseler
NPI 1144454257
$9,769.55
in general payments reported to CMS, 2019-2025
12 companies · $90.03 in 2025
The $90.03 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.94 · 2020: $138 · 2022: $103 · 2023: $4,488 · 2024: $4,934 · 2025: $90.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,610 · Honoraria: $1,665 · Travel and Lodging: $1,519 · Food and Beverage: $718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,610.00 |
| Honoraria | $1,665.00 |
| Travel and Lodging | $1,518.94 |
| Food and Beverage | $718.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $6,825.95 | 2023-2024 | Qinlock, Vimseltinib |
| Springworks Therapeutics, INC. | $2,413.44 | 2024 | Ogsiveo |
| Alexion Pharmaceuticals, INC. | $127.14 | 2023 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $102.87 | 2022 | |
| Merck Sharp & Dohme LLC | $99.36 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $55.62 | 2025 | Tagrisso |
| Aadi Bioscience, INC. | $55.45 | 2023 | Fyarro |
| Janssen Biotech, INC. | $38.37 | 2020 | |
| Jazz Pharmaceuticals INC. | $20.00 | 2025 | |
| Genentech USA, INC. | $16.94 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.41 | 2025 | Opdualag |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Eiseler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.